Erik Rasmussen
Overview
Explore the profile of Erik Rasmussen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1802
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Post A, Ho N, Rasmussen E, Post I, Cho A, Hofer J, et al.
JAMIA Open
. 2023 Oct;
6(4):ooad089.
PMID: 37860604
Objectives: Using agile software development practices, develop and evaluate an architecture and implementation for reliable and user-friendly self-service management of bioinformatic data stored in the cloud. Materials And Methods: Comprehensive...
2.
Krogh S, Jensen T, Rolving N, Thomsen J, Hansen C, Werenberg C, et al.
Chiropr Man Therap
. 2022 Feb;
30(1):9.
PMID: 35193634
Background: International guidelines do not recommend routine imaging, including magnetic resonance imaging (MRI), and seek to guide clinicians only to refer for imaging based on specific indications. Despite this, several...
3.
Cuyun Carter G, Sheffield K, Gossai A, Huang Y, Zhu Y, Bowman L, et al.
Curr Med Res Opin
. 2021 May;
37(7):1179-1187.
PMID: 33970738
Objective: This retrospective observational study described baseline characteristics, real-world treatment patterns, and outcomes among patients with metastatic breast cancer treated with abemaciclib in the United States. Methods: De-identified electronic health...
4.
Krogh S, Jensen T, Rolving N, Laursen M, Thomsen J, Hansen C, et al.
Chiropr Man Therap
. 2021 Mar;
29(1):12.
PMID: 33761956
Background: Managing low back pain (LBP) often involves MRI despite the fact that international guidelines do not recommend routine imaging. To allow us to explore the topic and use this...
5.
Herbst R, Arkenau H, Bendell J, Arrowsmith E, Wermke M, Soriano A, et al.
J Thorac Oncol
. 2020 Oct;
16(2):289-298.
PMID: 33068794
Introduction: Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324). Methods: In this multicenter, open-label phase 1a/b trial, patients received ramucirumab...
6.
Razak A, Cleary J, Moreno V, Boyer M, Calvo Aller E, Edenfield W, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33046621
Background: To determine the safety and efficacy of the anti-colony-stimulating factor 1 receptor (anti-CSF1R) monoclonal antibody AMG 820 in combination with pembrolizumab in patients with select solid tumors. Patients And...
7.
Lee H, Raje N, Landgren O, Upreti V, Wang J, Avilion A, et al.
Leukemia
. 2020 Apr;
35(1):255-258.
PMID: 32317775
No abstract available.
8.
Topp M, Duell J, Zugmaier G, Attal M, Moreau P, Langer C, et al.
J Clin Oncol
. 2020 Jan;
38(8):775-783.
PMID: 31895611
Purpose: The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma. Patients And Methods: In this first-in-human study, up to 10 cycles of AMG...
9.
Gluck W, Gounder M, Frank R, Eskens F, Blay J, Cassier P, et al.
Invest New Drugs
. 2019 Jul;
38(3):831-843.
PMID: 31359240
Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In...
10.
Erba H, Becker P, Shami P, Grunwald M, Flesher D, Zhu M, et al.
Blood Adv
. 2019 Jun;
3(13):1939-1949.
PMID: 31253596
This open-label, phase 1 study evaluated the safety, pharmacokinetics, and maximum tolerated dose of AMG 232, an investigational oral, selective mouse double minute 2 homolog inhibitor in relapsed/refractory acute myeloid...